UK markets close in 40 minutes

Spero Therapeutics, Inc. (SPRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.8145-0.0355 (-4.18%)
As of 10:48AM EDT. Market open.

Spero Therapeutics, Inc.

675 Massachusetts Avenue
14th Floor
Cambridge, MA 02139
United States
857 242 1600
https://sperotherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees35

Key executives

NameTitlePayExercisedYear born
Dr. Ankit Mahadevia M.D., MBACo-Founder, Pres, CEO & Director924.28k69.46k1981
Mr. Satyavrat Shukla C.F.A.CFO & Treasurer788.84kN/A1972
Ted JenkinsVP & Head of Investor RelationsN/AN/AN/A
Ms. Tamara Lynn Joseph L.L.M.Chief Legal OfficerN/AN/A1963
Mr. James P. BradyChief Human Resource OfficerN/AN/AN/A
Mr. Timothy KeutzerChief Devel. OfficerN/AN/A1968
Dr. Ian A. CritchleyHead of Clinical MicrobiologyN/AN/AN/A
Dr. Susannah Walpole Ph.D.Head of Clinical OperationsN/AN/AN/A
Dr. Angela TalleySr. VP of Clinical Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Spero Therapeutics, Inc.’s ISS governance QualityScore as of 31 July 2022 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.